A New Era for Morton's Neuroma Treatment?

A recent report in MedCentral highlights that the FDA has granted fast-track designation to a new, nonopioid injection therapy for Morton's neuroma — a condition that currently has no FDA-approved treatment. For the many patients living with this painful nerve condition, any progress toward recognised, regulated options is a significant development worth watching.

Our take: We will continue to monitor developments with CNTX-4975 and similar injection therapies closely. If a treatment of this kind becomes available and is supported by good clinical evidence, we would certainly consider its role in the co-management of selected patients with Morton’s neuroma-type pain.

However, careful patient selection will be important. Morton’s neuroma, or bursa neuroma complex, can vary considerably in size, chronicity and tissue change. In long-standing cases, particularly where the neuroma is large or there is significant mechanical irritation between the metatarsals, it remains to be seen whether a pain-modulating injection alone would be sufficient to resolve symptoms in a durable way.

That said, the concept is very interesting. A targeted non-opioid injection that works through pain pathways rather than inflammation could offer a useful alternative to steroid injections. Steroid injections can provide short-term relief for some patients, but the benefit is often temporary and repeated use may carry risks, including local fat-pad atrophy, skin thinning and damage to surrounding soft tissues.

For this reason, any regulated treatment that can reduce neuroma pain while avoiding some of the limitations of steroid injections deserves serious attention. At the London Podiatry Centre, our approach would remain evidence-based: we would want to see robust data on safety, duration of benefit, patient selection and outcomes compared with existing treatments such as orthoses, cryosurgery and surgical options.

In short, this is a development worth watching. It may not be the answer for every patient, especially those with chronic or larger neuromas, but it could become an important addition to the treatment pathway if future evidence supports its use.

About the author
Mr Ron McCulloch — Consultant Podiatric Surgeon, Centre Director, and specialist in clinical biomechanics, gait analysis and Morton's neuroma.

Source: MedCentral · https://londonpodiatry.com/en/specialities/mortons-neuroma/